Organon Acquires Dermavant Sciences, Including VTAMA (tapinarof)

NovaBay Pharmaceuticals Acquires DERMAdoctor

September 28, 2021

Consumer Products

NovaBay Pharmaceuticals, Inc. has entered into a definitive agreement to acquire DERMAdoctor, LLC for $15.0 million ( $12.0 million cash at closing plus up to $3.0 million in earnouts). The deal brings DERMAdoctor's ~30-product skincare portfolio and its 13-person team (co-founders Audrey and Jeff Kunin to remain) into NovaBay's commercial platform to expand its presence in the U.S. beauty market and capture revenue and operating synergies.

DermBiont Acquires SeylanMED to Expand Dermatology Pipeline

October 21, 2020

Biotechnology

DermBiont, a Boston-based clinical-stage precision dermatology company, has acquired SeylanMED, adding a targeted topical AKT inhibitor gel candidate for seborrheic keratosis to its pipeline. The acquisition expands DermBiont's therapeutic modalities and accelerates its objective to develop targeted topical treatments and live bacterial therapeutics for skin diseases.

Versant Diagnostics Acquires Cutaneous Pathology, P.A.

August 20, 2024

Healthcare Services

Versant Diagnostics, an independent physician services company based in Grapevine, Texas, has acquired Cutaneous Pathology, P.A., a dermatopathology practice in Winston-Salem, North Carolina. As part of the transaction, internationally recognized dermatopathologist Dr. Omar P. Sangueza has joined Versant to expand its national network of dermatopathology specialists.

Organon Acquires U.S. Rights to TOFIDENCE (tocilizumab-bavi) from Biogen

April 1, 2025

Pharmaceuticals

Organon has acquired regulatory and commercial rights in the United States for TOFIDENCE (tocilizumab-bavi), a biosimilar to Actemra, from Biogen. The deal includes an upfront payment to Biogen and Organon will assume tiered royalty and milestone obligations while Bio‑Thera Solutions will retain manufacturing rights for the U.S. market.

Vividion Therapeutics Acquires Tavros Therapeutics

January 12, 2025

Biotechnology

Vividion Therapeutics, a wholly owned subsidiary of Bayer AG, has acquired precision oncology platform company Tavros Therapeutics. The acquisition expands Vividion’s functional genomics and genomic screening capabilities, combining Tavros’s platform with Vividion’s chemoproteomics expertise to accelerate discovery of novel targets in oncology and immunology; financial terms were not disclosed.

Croda International Acquires Avanti Polar Lipids

July 6, 2020

Pharmaceuticals

Croda International Plc has agreed to acquire Avanti Polar Lipids, a US-based developer and manufacturer of high-purity lipids and lipid-based drug delivery solutions. The deal brings Avanti's research product portfolio and cGMP pharmaceutical services into Croda's Life Sciences sector to expand capabilities in drug delivery, vaccine adjuvants and cGMP manufacturing for biotechnology and pharmaceutical customers worldwide.